Centessa Pharmaceuticals plc (CNTA) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant polycystic kidney disease.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $40.50, CNTA has negative trailing earnings (P/E not meaningful) and an ROE of -60.37%. Market capitalisation stands at $6.3B.
Balance sheet quality for CNTA: current ratio of 8.6, net cash position of $287.0M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $40.50 |
| Market Cap | $6.3B |
| Exchange | NASDAQ |
| Country | GB |
Valuation Ratios
| Price / Book | 12.76 |
| EV / EBITDA | -23.84 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -60.37% |
| Return on Invested Capital | -42.41% |
| Return on Assets | -39.05% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 9.53 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 9.85 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CNTA | Centessa Pharmaceuticals plc | $6.3B | 12.76 | -60.4% | |
| NAMS | NewAmsterdam Pharma Company N.V. | $2.5B | 5.45 | -29.8% | |
| EWTX | Edgewise Therapeutics, Inc. | $4.9B | 10.73 | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
Price Performance
| 1 month | +0.00% |
| 3 months | +1.20% |
| Year-to-date | +61.94% |
| 1 year | +85.35% |
| 3 years | +524.04% |
| 5 years | +115.65% |
52-Week Range
| 52-week High | $40.56 |
| 52-week Low | $12.75 |
| Avg Volume (90d) | 2.4M |
Related companies: CGEM · CMPX · DSGN · EWTX · GLUE · IPSC · IVA
Explore sector: Healthcare · Biotechnology
More sections of CNTA: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks